One Year Data From St. Jude Medical (STJ) Study Demonstrates Safe, Rapid and Sustained Blood Pressure Reduction With EnligHTN Renal Denervation Technology
5/23/2013 10:50:45 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that the company’s EnligHTN™ Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after one year. The new one year study data from the EnligHTN I trial was presented today at EuroPCR 2013 in Paris.
Help employers find you! Check out all the jobs and post your resume.
comments powered by